Quest Diagnostics Stock: What Medicare Cuts Reveal About Pricing Power

Quest Diagnostics entered September with strong operating momentum. Second-quarter revenue grew 10.2% year over year, adjusted earnings per share increased 19.1%, and management raised its full-year revenue and earnings guidance.

Then a different kind of information arrived. On September 21, the Centers for Medicare & Medicaid Services released preliminary 2027 laboratory reimbursement rates showing that Medicare has been paying materially more than private insurers for many clinical laboratory tests. CMS now intends to bring those rates closer together.

The development has little to do with whether people need diagnostic testing. It has much more to do with who controls the price.

That makes Quest an interesting case study in a part of fundamental analysis that is easy to overlook. A company can have scale, recurring demand and operational efficiency while still having limited pricing power over an important customer.

The proposed Medicare changes are substantial

CMS said on September 21 that Medicare currently pays about 16% more for laboratory services than private payers. The agency estimates that aligning rates more closely with the private market could save taxpayers approximately $1 billion per year.

The underlying data show how broad the adjustment could be. Of roughly 1,500 laboratory test codes with a calculated private-payer weighted median, 1,171 had a lower rate than the current 2026 Medicare payment. Only 186 had a higher rate and 169 were unchanged.

The reductions will not all occur at once. Federal law caps the annual payment reduction for an individual clinical diagnostic laboratory test at 15% from 2027 through 2029. CMS expects to finalize the calendar-year 2027 rates in November, with the new schedule becoming effective January 1.

This is still a preliminary process. The final rates may differ after the comment period, so treating the maximum 15% reduction as a known company-wide earnings impact would create more precision than the current evidence supports.

Quest has been growing strongly

The timing is interesting because Quest's latest quarterly results were strong. Q2 revenue reached $3.04 billion, up 10.2% from a year earlier, with the company reporting 10.0% organic revenue growth. Adjusted diluted earnings per share increased 19.1% to $3.12.

Management also raised full-year guidance. Quest now expects 2026 revenue of $11.95 billion to $12.05 billion, representing growth of approximately 8.3% to 9.2%, and adjusted diluted earnings per share of $11.05 to $11.25.

Nothing in the CMS announcement changes the fact that testing demand has been strong. It changes one of the economic inputs attached to part of that demand.

This distinction matters. Volume growth answers how much service the company provides. Reimbursement determines how much value it captures for providing it.

A customer can be important without being the majority

Quest disclosed in its 2025 Form 10-K that Medicare and Medicaid programs represented approximately 11% of consolidated revenue. That percentage is meaningful, but investors should be careful about turning it directly into an estimated earnings hit.

The 11% figure combines Medicare and Medicaid, while the current CMS announcement relates specifically to the Medicare Clinical Laboratory Fee Schedule. Different tests also face different proposed rate changes. Some rates rise, some remain unchanged and others decline, subject to the annual reduction cap.

Simply multiplying 11% of Quest's revenue by 15% would therefore produce a neat number rather than a reliable one.

The broader insight is more useful. A meaningful portion of Quest's economics depends on reimbursement rates that the company does not determine itself.

Pricing power looks different in healthcare

When investors discuss pricing power, they often think about consumer brands. A company with a strong brand may be able to raise prices without losing many customers. In business-to-business markets, switching costs or mission-critical products can create a similar advantage.

Healthcare introduces another layer because the person receiving the service is often not the party setting the reimbursement rate. Patients need the test, physicians order it, laboratories perform it, and insurers or government programs determine much of what ultimately gets paid.

A laboratory can therefore have substantial demand and still face price pressure.

This is why market share and pricing power should not be treated as synonyms. Quest serves an enormous network of physicians, hospitals, health plans and patients. That scale can support efficiency, distribution and negotiating leverage. It does not mean the company can freely determine reimbursement from every payer.

Scale still has economic value

The reimbursement risk should not lead to the opposite mistake either. Limited pricing control in one part of the business does not mean scale has no value.

Large laboratories can spread logistics, automation, testing equipment, technology and administrative infrastructure across enormous test volumes. Quest has also been consolidating hospital outreach laboratories and expanding advanced diagnostics, health-plan relationships and direct-to-consumer testing.

Those capabilities can help offset pricing pressure through productivity and mix. Quest reported that it continues to deploy automation and AI across laboratories and administrative processes, while its Invigorate productivity program targets recurring efficiency improvements.

But efficiency and pricing power are still different sources of economic value. Lowering the cost per test can protect margins when reimbursement falls. It does not change who sets the reimbursement rate.

MOATEY currently sees limited moat evidence

MOATEY's latest stored assessment gives Quest 5 of 20 available Moat points. The current Earnings Power Value versus Net Reproduction Value assessment shows EPV below NRV, while the historical moat trend is classified as stagnant.

That framework assessment was last updated before the September 21 CMS announcement, so the reimbursement news should be treated as new external evidence rather than something already reflected in those figures.

The current moat score is still relevant because it shows that MOATEY was already cautious about translating Quest's scale into evidence of durable superior economics. The new Medicare development gives investors another analytical question to add to that picture.

Can Quest's network, efficiency and advanced-testing portfolio create enough economic value to offset pricing pressure from large payers over time?

That is more useful than asking whether Quest simply has a moat or does not. Competitive advantage exists through the economics it produces, not through the size of the company alone.

Financial strength and pricing power are separate

Quest currently receives 15 of 15 MOATEY points for Financial Health. That matters because reimbursement pressure becomes more dangerous when a company already has a fragile balance sheet or limited ability to absorb temporary margin compression.

Quest's current financial-health evidence is much stronger than its Growth or Moat evidence. MOATEY assigns only 0.8 of 15 points to Growth and currently classifies the company as a No Grower based on its multi-year framework measures.

Again, those measures do not mean Q2 revenue failed to grow. MOATEY's classifications evaluate a broader multi-year record and may use proprietary adjustments rather than reproducing individual reported quarters.

The contrast is useful. A company can be financially healthy while still facing structural questions around growth and pricing power.

What investors should not conclude from the announcement

The CMS proposal does not mean Quest's revenue will suddenly decline 15%. The reductions apply at the test-code level, the current rates are preliminary and the impact depends on the mix of tests reimbursed through the Medicare schedule.

It also does not mean diagnostic demand is weakening. Quest's latest results suggest exactly the opposite. Utilization remains healthy and the company raised its 2026 outlook in July.

The right interpretation sits between those extremes. The reimbursement changes represent a possible reduction in the economics attached to part of an otherwise healthy demand stream.

This is a recurring pattern in regulated and quasi-regulated industries. Demand can remain strong while the value captured per unit changes because an external party controls part of the economics.

That is why fundamental analysis has to look beyond revenue growth. Investors need to understand not only who buys a company's product, but also who ultimately determines the price.

What matters from here

The first thing to watch is the final Medicare fee schedule in November. The preliminary data provide a strong indication of direction, but the final rates will determine which test categories face the largest reductions and how quickly those changes affect Quest's reimbursement mix.

The second question is whether Quest can offset lower reimbursement elsewhere. Productivity gains, test-volume growth, favorable mix shifts and expansion in advanced diagnostics could absorb part of the pressure. If the company can preserve margins despite lower rates, that would provide useful evidence about the economic value of its scale.

Investors should also watch organic growth rather than relying only on acquisition-driven expansion. Acquisitions can add revenue, but recurring pricing pressure eventually has to be absorbed by the combined economics of the business.

The broader lesson goes well beyond diagnostic laboratories. A business can have millions of customers, essential services and significant market share without controlling every important price in its value chain.

Quest's latest results show healthy demand. The CMS announcement asks a different question: how much of the value created by that demand can Quest sustainably keep?